Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...
The Montair LC tablet is an antiallergic tablet that relieves sneezing, itching, watery eyes, stuffy nose, and runny nose ...
3h
THE cold weather can trigger a range of symptoms, with the most common being shivering. But if certain symptoms seem out of ...
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...
Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.
INF-904 is under clinical development by InflaRx and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase ...
Adam Friedman, MD: Hello, and welcome to Medscape Care Cues. I'm Dr Adam Friedman and I'm joined by my good friend and colleague, Dr Shawn Kwatra. Welcome, Shawn. Shawn G. Kwatra, MD: Thanks so ...
Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...
Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...
Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm ...
Despite positive preliminary data from its early stage study of treating hives, Jasper Therapeutics Inc. saw its stock drop dramatically on Jan. 8. Results were from the ongoing phase Ib/IIa study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback